DrugPatentWatch Database Preview

Details for Patent: 7,803,839

Which drugs does patent 7,803,839 protect, and when does it expire?

Patent 7,803,839 protects COTELLIC and is included in one NDA.

This patent has forty-five patent family members in thirty countries.

Summary for Patent: 7,803,839

Title:	Azetidines as MEK inhibitors for the treatment of proliferative diseases
Abstract:	Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Inventor(s):	Aay; Naing (San Mateo, CA), Anand; Neel Kumar (Burlingame, CA), Blazey; Charles M. (San Francisco, CA), Bowles; Owen Joseph (Pacifica, CA), Bussenius; Joerg (Foster City, CA), Costanzo; Simona (Los Altos, CA), Curtis; Jeffry Kimo (San Anselmo, CA), DeFina; Steven Charles (Burlingame, CA), Dubenko; Larisa (San Francisco, CA), Joshi; Anagha Abhijit (Fremont, CA), Kennedy; Abigail R. (Oakland, CA), Kim; Angie Inyoung (San Mateo, CA), Koltun; Elena S. (Foster City, CA), Manalo; Jean-Claire Limun (Daly City, CA), Peto; Csaba J. (Alameda, CA), Rice; Kenneth D. (San Rafael, CA), Tsang; Tsze H. (El Cerrito, CA)
Assignee:	Exelixis, Inc. (South San Francisco, CA)
Application Number:	11/995,928
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,803,839

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Genentech Inc	COTELLIC	cobimetinib fumarate	TABLET;ORAL	206192-001	Nov 10, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Foreign Priority and PCT Information for Patent: 7,803,839

PCT Information
PCT Filed	October 05, 2006	PCT Application Number:	PCT/US2006/039126
PCT Publication Date:	April 19, 2007	PCT Publication Number:	WO2007/044515

Non-Orange Book US Patents Family Members for Patent 7,803,839

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
2,017,166,523		➤ Sign Up
8,362,002	Azetidines as MEK inhibitors for the treatment of proliferative diseases	➤ Sign Up
7,915,250	Azetidines as MEK inhibitors for the treatment of proliferative diseases	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 7,803,839

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	504565	➤ Sign Up
Australia	2006302415	➤ Sign Up
Brazil	PI0617165	➤ Sign Up
Canada	2622755	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,803,839

Foreign Priority and PCT Information for Patent: 7,803,839

For more information try a trial or see the plans and pricing